Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.

Study summary

A study of whether mobile devices can improve the detection of pulmonary AEs (including pneumonitis) in stage III NSCLC patients post-CRT, while on durvalumab.

Ask AI to explain this study

Start here

Key things to know

Main goalOther

This describes the study’s primary purpose.

What is being studiedMultiparametric Mobile Technology

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC) · Early-stage or resectable · Locally advanced

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jun 22, 2023 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 4

Interventional

Where is it offered?18 U.S. locations

Locations may change over time.

Who runs it?AstraZeneca

Study sponsor

Study overview

What this study is about

Purpose: Other
Study type: Interventional
Phase: Phase 4
Sponsor: AstraZeneca
Interventions being studied: Device: Multiparametric Mobile Technology

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Non-small cell lung cancer (NSCLC)→

Disease setting

Early-stage or resectable→Locally advanced→

Treatment approach

Immunotherapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Select
Patient has unresectable Stage III NSCLC that has not progressed following concurrent platinum-based chemotherapy and radiation therapy and is eligible to receive durvalumab according to the US FDA approved package insert.
Patient is able and willing to use the mobile application and connected devices.
Patient is able to complete QoL assessments. Select

Reasons someone may not be able to joinExclusion criteria

Patient is currently oxygen dependent.
Patient has comorbidities that will prevent consistent and reliable measurement assessments with multiparametric mobile technology including severe chronic obstructive pulmonary disorder (COPD), severe asthma, congestive heart failure \[CHF\], interstitial lung disease \[ILD\], and others.
Patients on other immunotherapy or systemic immunosuppressants.
Patients with active or prior autoimmune disease or history of immunodeficiency.
Currently pregnant women.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Research SiteLong Beach, California
Research SiteSanta Ana, California
Research SiteEnglewood, Colorado
Research SitePlainville, Connecticut
Research SiteBoca Raton, Florida
Research SiteTallahassee, Florida
Research SiteTampa, Florida
Research SiteAtlanta, Georgia
Research SiteWestwood, Kansas
Research SiteLouisville, Kentucky
Research SitePontiac, Michigan
Research SiteNew York, New York

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 22, 2023. Always confirm current availability with the study team.

View original record ↗